Health eHeart BioBank

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

500000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

NCT02543996

Undiagnosed Diseases Cardiovascular Disease

RECRUITING

Genetic Markers of Coronary Heart Disease in Type 2 Diabetes

NCT00078052

Cardiovascular Diseases Coronary Disease Diabetes Mellitus, Non-insulin Dependent +2 more

COMPLETED

Cardiovascular and Metabolic Sciences Biorepository

NCT06560424

Cardiovascular Diseases Metabolic Disease

RECRUITING

Biomarkers of Inherited Cardiovascular Conditions

NCT02804256

Cardiomyopathy Ischemic Heart Disease

UNKNOWN

GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease

NCT00590200

Cardiovascular Diseases

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Diseases Cardiac Diseases Vascular Diseases Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with a History of Cardiovascular Disease

Blood Draw

Intervention Type PROCEDURE

Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.

Tissue Collection

Intervention Type PROCEDURE

If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.

DNA Collection

Intervention Type PROCEDURE

Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.

Medical Chart Review

Intervention Type OTHER

Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Participants with a Family History of Cardiovascular Disease

Blood Draw

Intervention Type PROCEDURE

Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.

Tissue Collection

Intervention Type PROCEDURE

If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.

DNA Collection

Intervention Type PROCEDURE

Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.

Medical Chart Review

Intervention Type OTHER

Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Healthy Controls

Blood Draw

Intervention Type PROCEDURE

Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.

Tissue Collection

Intervention Type PROCEDURE

If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.

DNA Collection

Intervention Type PROCEDURE

Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.

Medical Chart Review

Intervention Type OTHER

Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Draw

Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.

Intervention Type PROCEDURE

Tissue Collection

If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.

Intervention Type PROCEDURE

DNA Collection

Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.

Intervention Type PROCEDURE

Medical Chart Review

Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medical Record Review

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years or older.

And at least one of the following:

* Established patient seen at UCSF and/or is a current participant in a clinical study that utilizes the HeH BioBank for biospecimen collection.
* Family member of a patient with cardiovascular disease.
* Patient with no cardiovascular disease.

Exclusion Criteria

* Unwilling to consent to biospecimen collection through the HeH BioBank.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR